Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I
- None.
- None.
The strategic partnership between Evotec and Owkin leverages artificial intelligence in the biopharmaceutical sector, with potential to significantly expedite the drug discovery process. This collaboration is poised to enhance the efficiency and efficacy of identifying novel drug targets and developing new therapeutics, particularly in areas such as oncology, immunology and inflammation. The use of A.I. in analyzing multimodal patient data for target discovery is a progressive step in personalized medicine, potentially leading to more effective treatments with fewer side effects.
From an industry perspective, this partnership underscores the growing trend of integrating A.I. into traditional R&D processes. It is indicative of a broader shift towards data-driven discovery methods that can lead to a reduction in time and cost for drug development. For stakeholders, the success-based milestones and royalty structure provide a balanced risk-reward scenario, aligning the incentives of both parties towards the successful commercialization of new drugs.
The financial implications of the partnership between Evotec and Owkin are multifaceted. Evotec stands to gain from R&D funding, milestone payments and future royalties, which can lead to diversified revenue streams and potentially enhance shareholder value. Owkin benefits from the shared R&D platform, which can reduce its capital expenditure and operational risks associated with drug discovery and development. For the stock market, this collaboration could be a positive signal for Evotec's investors, reflecting the company's ability to monetize its platform and expertise.
Additionally, the agreement may impact the valuation of both companies, as the market often responds favorably to innovative partnerships that promise to accelerate product pipelines. However, the actual financial impact will depend on the successful progression of the drug candidates through the development phases and their eventual market success, which is inherently uncertain in the pharmaceutical industry.
The convergence of A.I. and life sciences represented by the Evotec-Owkin partnership is a significant development in the healthcare industry. This collaboration could set a precedent for how biotech and pharma companies approach R&D, potentially leading to a more streamlined path from discovery to clinical trials. The joint Research Strategy Team, comprising experienced drug hunters, is a strategic move to ensure that the programmes are not only scientifically sound but also commercially viable.
The partnership's focus on therapeutic areas with high unmet needs suggests a commitment to addressing critical healthcare challenges. By combining Owkin's A.I. capabilities with Evotec's drug discovery expertise, the collaboration may yield innovative treatments that could improve patient outcomes and address gaps in current treatment options. This has long-term implications for healthcare delivery and could influence future strategic alignments in the industry.
- PARTNERSHIP COMBINES OWKIN'S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM
- A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN'S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC
- AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC
HAMBURG, GERMANY and PARIS, FRANCE / ACCESSWIRE / January 4, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation ("I&I").
The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and develop new therapeutics. Harmonising Owkin's cutting-edge target discovery engine with Evotec's end-to-end shared R&D platforms and disease biology expertise will accelerate Owkin's novel programmes from the discovery phase to the clinic.
Owkin will identify indication-relevant targets and subgroups using A.I. applied to multimodal patient data. Evotec will leverage its shared R&D platform to accelerate and de-risk the validation of targets, identification of drug candidates and successful completion of pre-clinical development activities up to IND. An Owkin-Evotec joint Research Strategy Team formed of highly experienced drug hunters will drive the collaboration, designing fully tailored strategic programme plans from target selection to IND and ensuring delivery of the programmes. The partnership also enables Owkin to maximise capital efficiency while reducing risk. Evotec will receive R&D funding from Owkin and is eligible to earn performance milestone payments and royalties on product sales.
Dr Matthias Evers, Chief Business Officer of Evotec, commented: "Owkin and Evotec both feel there is something special brewing by convergence between A.I. and science in drug innovation - hence, we are thrilled to strike this partnership towards accelerating therapeutics in therapeutic areas of highest unmet needs - patients need us, together."
Dr Thomas Clozel, Co-founder and CEO of Owkin, remarked: "The combination of in silico hypothesis generation through A.I. and experimental lab validation is the core of our pipeline strategy. Evotec's broad capabilities in drug discovery, which range all the way from target validation through to IND-enabling studies, coupled with their understanding of artificial intelligence and its implementation in their workflows make them an ideal partner for us."
ABOUT OWKIN
Owkin is a TechBio company that combines the best of human and artificial intelligence to ensure every patient gets the right treatment. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and develop AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI's potential to power precision medicine. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation.
Owkin founded MOSAIC , the world's largest multi-omics atlas for cancer research.
Owkin has raised over
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn .
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications, Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications, Hinnerk.Rohwedder@evotec.com
IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG, Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
What is the partnership between Evotec SE and Owkin about?
What are the key focus areas of the collaboration?
How will the collaboration accelerate Owkin's novel programmes?
What are the benefits of the partnership for Owkin?
What are the financial aspects of the partnership?
What is Dr. Matthias Evers' comment on the partnership?
What is Dr. Thomas Clozel's view on the partnership?
